Operating Characteristics of the Simulated Healthy Participant Approach in Impaired Clearance Studies
- 22 January 2025
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (1) , 1-8
Abstract
Minimizing harm is a cornerstone of ethical research practices. A drug that has undergone extensive clinical pharmacological testing in healthy participantKeywords
This publication has 10 references indexed in Scilit:
- Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the ApproachThe AAPS Journal, 2024
- Feasibility of Using Population Pharmacokinetics‐Based Virtual Control Groups in Organ Impairment StudiesThe Journal of Clinical Pharmacology, 2024
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug DevelopmentClinical Pharmacokinetics, 2023
- Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib PharmacokineticsThe AAPS Journal, 2023
- Design and conduct considerations for studies in patients with hepatic impairmentClinical and Translational Science, 2022
- Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic PredictionsThe Journal of Clinical Pharmacology, 2021
- Design and conduct considerations for studies in patients with impaired renal functionClinical and Translational Science, 2021
- Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry PerspectiveClinical Pharmacology & Therapeutics, 2020
- Evaluation of Model‐Based Prediction of Pharmacokinetics in the Renal Impairment PopulationThe Journal of Clinical Pharmacology, 2017
- Abstracts Accepted for American Conference on Pharmacometrics 2015 (ACoP6)Journal of Pharmacokinetics and Pharmacodynamics, 2015